#18
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Michigan’s cannabis industry is facing significant economic pressure as state lawmakers consider repealing a recently implemented 24% excise tax that has generated approximately $3 billion in revenue. The tax increase has reportedly reduced consumer demand and disadvantaged legal retailers competing against illicit market alternatives, which offer lower prices without tax burden. For clinicians and patients, this regulatory uncertainty directly impacts access and affordability of legal cannabis products, particularly for those using cannabis therapeutically for conditions like chronic pain, nausea, or epilepsy-related seizures. Tax-driven price increases may push patients toward unregulated black market products with unknown potency, contaminants, and quality standards, undermining clinical safety and the ability to monitor standardized dosing. Additionally, reduced tax revenue threatens funding for cannabis research, education, and public health initiatives that support evidence-based clinical practice. Clinicians should remain aware of their patients’ cost barriers to accessing regulated products and consider how local tax policy influences medication adherence and the risk of exposure to untested cannabis formulations.
“Michigan’s proposed 24% tax increase fundamentally misunderstands how cannabis patients respond to pricing, and I’ve seen this play out clinically for two decades: when legal products become unaffordable, patients don’t stop using cannabis, they return to illicit sources where we lose all quality control and dosing reliability. The state should recognize that a sustainable cannabis tax policy requires keeping legal products competitive enough that patients with legitimate therapeutic needs can actually access them.”
? Michigan’s proposed 24% tax increase on cannabis—intended to fund public health and regulatory infrastructure—faces industry pushback that could reshape market dynamics and ultimately affect patient access and product safety in clinical settings. While higher taxes theoretically reduce consumption and increase revenue for harm-reduction programs, they may also drive patients toward illicit markets where quality control is absent, potentially exposing users to contaminated or mislabeled products with unpredictable cannabinoid profiles. Clinicians should recognize that tax policy operates as an upstream social determinant of cannabis use patterns; lower retail prices from tax repeals may increase patient use and associated healthcare burdens, while aggressive taxation could paradoxically worsen outcomes for those who self-medicate for chronic pain or mental health conditions by reducing legitimate access. The complexity here involves balancing public health revenue needs against unintended consequences of pricing mechanisms on vulnerable populations. Practical guidance for providers should include explicit screening conversations about cannabis sour
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
